Shanghai Chest Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 42 Carcinoma, Non-Small-Cell Lung studies with Shanghai Chest Hospital as lead sponsor. 22 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 18Phase 3 7Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pulsed Field Ablation for the Treatment of Malignant Lung TumorsNot yet recruitingNCT07889297Not applicable
• Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung CancerNot yet recruitingNCT07780591Not applicable
• Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLCNot yet recruitingNCT07698990Not applicable
• SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07662811Phase 2/3
• Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07632365Phase 1/2
• Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)RecruitingNCT07564557Not applicable
• A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingNCT06982924Phase 2
• Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung CancerEnrolling by invitationNCT06962449
• Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLCNot yet recruitingNCT06904547
• Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung CancerRecruitingNCT06730503
• A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLCNot yet recruitingNCT06690671Phase 1/2
• Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCRecruitingNCT06663306Phase 1
• Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung CancerRecruitingNCT06659042Phase 2
• Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung CancerNot yet recruitingNCT06580665Not applicable
• Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLCNot yet recruitingNCT06483009Phase 4
• Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)RecruitingNCT06437977Phase 3
• Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) ScanRecruitingNCT06358222
• Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLCRecruitingNCT06127303Phase 2
• Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare MutationsRecruitingNCT05701787
• First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
• Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLCNot yet recruitingNCT05218759Not applicable
• Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung CancerRecruitingNCT04977791
• Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）Active, not recruitingNCT07076693Phase 2/3
• A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLCActive, not recruitingNCT06443684
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD EvaluationStatus unknownNCT05460195Phase 2
• Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsCompletedNCT04967079Phase 1
• Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCStatus unknownNCT04895930Phase 2
• To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionStatus unknownNCT04814056Phase 4
• Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC PatientsStatus unknownNCT04473703
• Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLCStatus unknownNCT04405674Phase 2
• Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 InsertionsStatus unknownNCT04382300Phase 2
• Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIBStatus unknownNCT04197076
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLCStatus unknownNCT03331575Phase 3
• To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerStatus unknownNCT02977169Phase 2
• Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT02975609Phase 2
• To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerTerminatedNCT02974426Phase 3
• 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical StudyStatus unknownNCT02938546Phase 3
• Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLCStatus unknownNCT02669719Phase 2
• Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)Status unknownNCT02338011Phase 2/3
• Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant ChemotherapyTemporarily not availableNCT01297101